FI3759092T3 - Yhdisteitä, jotka moduloivat ampa-reseptoritoimintaa - Google Patents
Yhdisteitä, jotka moduloivat ampa-reseptoritoimintaa Download PDFInfo
- Publication number
- FI3759092T3 FI3759092T3 FIEP19710107.4T FI19710107T FI3759092T3 FI 3759092 T3 FI3759092 T3 FI 3759092T3 FI 19710107 T FI19710107 T FI 19710107T FI 3759092 T3 FI3759092 T3 FI 3759092T3
- Authority
- FI
- Finland
- Prior art keywords
- alkyl
- compound according
- group
- pharmaceutically acceptable
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803340.7A GB201803340D0 (en) | 2018-03-01 | 2018-03-01 | Compounds |
| PCT/GB2019/050578 WO2019166822A1 (en) | 2018-03-01 | 2019-03-01 | Compounds that modulates ampa receptor function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3759092T3 true FI3759092T3 (fi) | 2024-01-18 |
Family
ID=61903711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19710107.4T FI3759092T3 (fi) | 2018-03-01 | 2019-03-01 | Yhdisteitä, jotka moduloivat ampa-reseptoritoimintaa |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11298345B2 (enExample) |
| EP (1) | EP3759092B1 (enExample) |
| JP (1) | JP7225255B2 (enExample) |
| KR (2) | KR20250093578A (enExample) |
| CN (1) | CN112004811B (enExample) |
| AU (1) | AU2019226718C1 (enExample) |
| BR (1) | BR112020017739A2 (enExample) |
| CA (1) | CA3091783A1 (enExample) |
| DK (1) | DK3759092T3 (enExample) |
| ES (1) | ES2970784T3 (enExample) |
| FI (1) | FI3759092T3 (enExample) |
| GB (1) | GB201803340D0 (enExample) |
| MX (1) | MX2020009097A (enExample) |
| PL (1) | PL3759092T3 (enExample) |
| RU (1) | RU2020127537A (enExample) |
| WO (1) | WO2019166822A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| WO2001096308A1 (en) | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| RU2279428C2 (ru) | 2000-09-18 | 2006-07-10 | Эйсай Ко., Лтд. | Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| WO2006109056A1 (en) | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| TW200812975A (en) | 2006-03-20 | 2008-03-16 | Glaxo Group Ltd | Compounds which potentiate AMPA receptor and uses thereof in medicine |
| ATE543798T1 (de) | 2006-04-24 | 2012-02-15 | Lilly Co Eli | Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1 |
| TW200817385A (en) | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| EP2086643B1 (en) | 2006-11-03 | 2011-03-23 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| GB0711088D0 (en) * | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| JP5451611B2 (ja) | 2007-07-26 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター |
| NZ584098A (en) | 2007-09-20 | 2012-05-25 | Cortex Pharma Inc | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| TW201004945A (en) | 2008-05-01 | 2010-02-01 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| TW201012803A (en) | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| TW201031649A (en) * | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| AU2010264095B2 (en) | 2009-06-26 | 2013-07-11 | Biogen Ma Inc. | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
| WO2011132051A2 (en) * | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2018
- 2018-03-01 GB GBGB1803340.7A patent/GB201803340D0/en not_active Ceased
-
2019
- 2019-03-01 KR KR1020257019599A patent/KR20250093578A/ko active Pending
- 2019-03-01 EP EP19710107.4A patent/EP3759092B1/en active Active
- 2019-03-01 DK DK19710107.4T patent/DK3759092T3/da active
- 2019-03-01 KR KR1020207025799A patent/KR102821949B1/ko active Active
- 2019-03-01 MX MX2020009097A patent/MX2020009097A/es unknown
- 2019-03-01 BR BR112020017739-3A patent/BR112020017739A2/pt unknown
- 2019-03-01 US US16/970,394 patent/US11298345B2/en active Active
- 2019-03-01 PL PL19710107.4T patent/PL3759092T3/pl unknown
- 2019-03-01 JP JP2020544266A patent/JP7225255B2/ja active Active
- 2019-03-01 FI FIEP19710107.4T patent/FI3759092T3/fi active
- 2019-03-01 RU RU2020127537A patent/RU2020127537A/ru unknown
- 2019-03-01 AU AU2019226718A patent/AU2019226718C1/en active Active
- 2019-03-01 CA CA3091783A patent/CA3091783A1/en active Pending
- 2019-03-01 CN CN201980016394.0A patent/CN112004811B/zh active Active
- 2019-03-01 WO PCT/GB2019/050578 patent/WO2019166822A1/en not_active Ceased
- 2019-03-01 ES ES19710107T patent/ES2970784T3/es active Active
-
2022
- 2022-03-04 US US17/687,296 patent/US12383540B2/en active Active
-
2025
- 2025-06-13 US US19/238,079 patent/US20250375432A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250375432A1 (en) | 2025-12-11 |
| EP3759092A1 (en) | 2021-01-06 |
| EP3759092B1 (en) | 2023-12-20 |
| CN112004811A (zh) | 2020-11-27 |
| ES2970784T3 (es) | 2024-05-30 |
| AU2019226718A1 (en) | 2020-09-03 |
| JP7225255B2 (ja) | 2023-02-20 |
| PL3759092T3 (pl) | 2024-04-08 |
| BR112020017739A2 (pt) | 2020-12-22 |
| AU2019226718A8 (en) | 2020-09-24 |
| JP2021515749A (ja) | 2021-06-24 |
| DK3759092T3 (da) | 2024-01-22 |
| KR20250093578A (ko) | 2025-06-24 |
| WO2019166822A1 (en) | 2019-09-06 |
| US20230000847A1 (en) | 2023-01-05 |
| AU2019226718C1 (en) | 2024-01-11 |
| KR20200128032A (ko) | 2020-11-11 |
| GB201803340D0 (en) | 2018-04-18 |
| AU2019226718B2 (en) | 2023-09-28 |
| RU2020127537A (ru) | 2022-04-26 |
| CN112004811B (zh) | 2023-09-22 |
| US20210113539A1 (en) | 2021-04-22 |
| CA3091783A1 (en) | 2019-09-06 |
| MX2020009097A (es) | 2020-10-08 |
| NZ767186A (en) | 2025-02-28 |
| US12383540B2 (en) | 2025-08-12 |
| US11298345B2 (en) | 2022-04-12 |
| KR102821949B1 (ko) | 2025-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50557A (fr) | Pistons pour dispositifs d'administration de médicament | |
| MY182403A (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| EP3939572C0 (en) | VEHICLES FOR THE CONTROLLED ADMINISTRATION OF DIFFERENT PHARMACEUTICAL AGENTS | |
| JP2015501783A5 (enExample) | ||
| MX2016006564A (es) | Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos. | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| CL2008001374A1 (es) | Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia. | |
| MY196243A (en) | Dihydropyrimidine Compounds and Their Application In Pharmaceuticals | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| JP2015514808A5 (enExample) | ||
| EA201792235A1 (ru) | Инъецируемые препараты замедленного высвобождения, содержащие изоксазолиновое действующее вещество, способы и применение | |
| EP2814486A4 (en) | ANTIVIRAL AGENT FOR THE TREATMENT OF ARENAVIRUS INFECTIONS | |
| JP2016501185A5 (enExample) | ||
| EP3616696A4 (en) | ORAL ENZALUTAMIDE-CONTAINING PHARMACEUTICAL COMPOSITION | |
| MD20140094A2 (ro) | Spiro [2.4]heptani pentru tratamentul infecţiilor cauzate de Flaviviridae | |
| EP3731846A4 (en) | DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTION | |
| MX388549B (es) | Uso terapeutico de compuestos. | |
| EP3471829A4 (en) | ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS | |
| EA201401276A1 (ru) | Способы с использованием хелатных комплексов олигонуклеотидов | |
| HRP20161208T1 (hr) | Derivati benzilidengvanidina i terapeutska upotreba za liječenje bolesti zbog pogrešnog savijanja proteina | |
| EP3454868A4 (en) | ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS | |
| HRP20211907T1 (hr) | Pirazol – oksazolidinon spoj za anti – hepatitis b virus | |
| JP2015500842A5 (enExample) | ||
| FI3830092T3 (fi) | Heteroaromaattiset NMDA-reseptorimodulaattorit ja niiden käytöt | |
| EP2754440A4 (en) | MEDICAMENT FOR TREATING AMYOTROPHER LATERAL SCLEROSIS OR PREVENTING THE PROGRESS OF AMYOTROPHER LATERAL SCLEROSIS |